Fulcrum Therapeutics® Announces Additional HBG mRNA Ind

Achieved mean 5.6-fold HBG mRNA induction at 20mg and mean 6.2-fold at 30mg after 14 days of once-daily dosing, further supporting potential of FTX-6058 to provide a functional cure Continues to be... | December 6, 2021

Related Keywords

Cambridge , Cambridgeshire , United Kingdom , Philadelphia , Pennsylvania , United States , Canada , Kaitlin Gallagher , Franke Weise , Bryan Stuart , Stephanie Ascher , Naomi Aoki , Christi Waarich , Gerd Blobel , Stern Investor Relations Inc , Drug Administration , Nasdaq , Embryonic Ectoderm Development , Replay International Number , Exchange Commission , International Number , Fulcrum Therapeutics Inc , Corporate Communications , Berry Company Public Relations , Clinical Development , Globenewswire Inc , Pediatric Hematology , Achieved Maximal , Higher Doses , Fold Induction , Hbf Master Regulators , Development Plans , Investigational New Drug , Investor Relations , Dial In Number , International Dial In Number , Ectoderm Development , Private Securities Litigation Reform Act , Vice President , Fulcrum Therapeutics , Nc Stock Exchange , News , Information , Press Release , Chieved , Sean , Bg , Rna , Nduction , It , 40mg , End , After , 4 , Ways , F , Urther , Supporting , Potential , O , Rovide , Unctional , Cure , Ontinues , O Fulc Us3596161097 ,